| Literature DB >> 22675462 |
Helen S Cohen1, Christopher Cox, Gayle Springer, Howard J Hoffman, Mary A Young, Joseph B Margolick, Michael W Plankey.
Abstract
BACKGROUND: Most HIV-seropositive subjects in western countries receive highly active antiretroviral therapy (HAART). Although many aspects of their health have been studied, little is known about their vestibular and balance function. The goals of this study were to determine the prevalences of vestibular and balance impairments among HIV-seropositive and comparable seronegative men and women and to determine if those groups differed.Entities:
Mesh:
Year: 2012 PMID: 22675462 PMCID: PMC3364989 DOI: 10.1371/journal.pone.0038419
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Enrollment characteristics of sample.
| HIV+ | HIV− | |||||
| Men | Women | All HIV+ | Men | Women | All HIV− | |
| Total, n | 126 | 121 | 247 | 168 | 32 | 200 |
| Age, mean (SD), yrs | 52.0 (8.0) | 45.6 (8.6) | 48.9 (8.9) | 56.7 (9.5) | 40.9 (10.2) | 54.2 (11.2) |
| Race, n (%) | ||||||
| Non-black | 58 (46.0) | 26 (21.5) | 84 (34.0) | 134 (79.8) | 9 (28.1) | 143 (71.5) |
| Black | 68 (54.0) | 95 (78.5) | 163 (66.0) | 34 (20.2) | 23 (71.9) | 57 (28.5) |
| Ever AIDS, n (%) | 22 (17.5) | 44 (36.4) | 66 (26.7) | |||
| Ever mono, n (%) | 37 (29.4) | 47 (38.8) | 84 (34.0) | |||
| Ever combo, n (%) | 59 (46.8) | 70 (57.9) | 129 (52.2) | |||
| Ever HAART, n (%) | 116 (92.1) | 99 (81.8) | 215 (87.0) | |||
| Current HAART, n (%) | 105 (83.3) | 85 (70.3) | 190 (76.9) | |||
| Nadir CD4+ T cell count, mean (SD) | 281.5 (174.1) | 258.6 (183.0) | 270.2 (178.5) | |||
| Current CD4+ T cell count, mean (SD) | 568.8 (277.0) | 543.6 (291.7) | 556.4 (284.0) | |||
| Peak CD8+ T cell count, mean (SD) | 1468.8 (699.8) | 1371.7 (656.5) | 1421.3 (679.3) | |||
| Current CD8+ T count, mean (SD) | 910.2 (403.4) | 805.4 (361.9) | 858.8 (386.4) | |||
| Undetectable HIV RNA, n (%) | 99 (78.6) | 60 (49.6) | 159 (64.4) | |||
| Log10 HIV RNA, median (IQR) | 3.94 (2.91, 4.45) | 3.44 (2.67, 4.40) | 3.50 (2.68, 4.42) | |||
Ever AIDS, ever diagnosed with AIDS; Ever mono, ever used monotherapy; Ever combo, ever used combination HAART and monotherapy; Ever HAART, ever used HAART. Undetectable HIV RNA, subjects with undetectable levels of HIV RNA; Log10 HIV RNA, log level of HIV RNA among HIV+ participants with detectable levels of RNA (n = 27 men and 61 women).
Frequency distribution of abnormal testing outcomes.
| HIV+, n (%) | HIV−, n(%) | |||||
| Men | Women | All HIV+ | Men | Women | All HIV− | |
| Total | 126 | 121 | 247 | 168 | 32 | 200 |
| Dix-Hallpike any nystagmus | 44 (37.3) | 49 (44.1) | 93 (40.6) | 58 (37.2) | 13 (40.6) | 71 (37.8) |
| Dix-Hallpike classical nystagmus | 1 (0.9) | 1 (0.9) | 2 (0.9) | 3 (1.9) | 4 (12.5) | 7 (3.7) |
| Dix-Hallpike nonclassical nystagmus | 43 (36.4) | 48 (43.2) | 91 (39.7) | 55 (35.3) | 9 (28.1) | 64 (34.0) |
| Head Thrust test | 12 (9.8) | 0 | 12 (5.0) | 35 (21.1) | 0 | 35 (17.7) |
| Romberg ECF | 21 (17.7) | 16 (13.6) | 37 (15.6) | 24 (14.7) | 3 (9.4) | 27 (13.9) |
| Spontaneous nystagmus | 5 (4.3) | 2 (1.8) | 7 (3.1) | 7 (4.4) | 3 (9.4) | 10 (5.2) |
| Gaze-evoked nystagmus | 47 (39.8) | 40 (36.4) | 87 (38.2) | 68 (42.8) | 12 (37.5) | 80 (41.9) |
Dix-Hallpike any nystagmus = Dix-Hallpike classical nystagmus+Dix-Hallpike nonclassical nystagmus.
Multivariable odds ratios (with 95% confidence intervals) from multiple logistic regression analysis for combined HIV+ and HIV−.
| Dix-Hallpike any nystagmus | Dix-Hallpike non-classical nystagmus | Romberg ECF | Gaze-evoked nystagmus | |
| Age per 10 yrs increase | 1.09 (0.87, 1.37) | 1.14 (0.91, 1.43) | 2.42 (1.73, 3.39) | 1.01 (0.81, 1.26) |
| Black vs. non-black | 1.03 (0.65, 1.62) | 1.06 (0.67, 1.68) | 1.89 (0.97, 3.69) | 0.50 (0.32, 0.8) |
| Female vs. male | 1.31 (0.8, 2.15) | 1.17 (0.71, 1.93) | 1.1 (0.54, 2.24) | 1.03 (0.62, 1.7) |
| HIV+ not HAART | 1.41 (0.72, 2.78) | 1.66 (0.84, 3.29) | 1.93 (0.73, 5.07) | 1.35 (0.67, 2.7) |
| HIV+ HAART | 0.98 (0.62, 1.54) | 1.17 (0.73, 1.85) | 1.43 (0.73, 2.8) | 1.04 (0.66, 1.63) |
Statistically significant at p<0.05.
Statistically significant at p<0.09.
Multivariable odds ratios (with 95% confidence intervals) from multiple logistic regression analysis for HIV+ only.
| Dix-Hallpike any nystagmus | Dix-Hallpike non-classical nystagmus | Romberg ECF | Gaze-evoked nystagmus | |
| Age per 10 yrs increase | 1.147 (0.8, 1.65) | 1.1 (0.76, 1.58) | 2.51 (1.49, 4.21) | 0.91 (0.63, 1.32) |
| Black vs. non-black | 1.419 (0.77, 2.61) | 1.32 (0.72, 2.43) | 1.33 (0.56, 3.13) | 0.47 (0.26, 0.87) |
| Female vs. male | 1.433 (0.75, 2.73) | 1.43 (0.75, 2.72) | 1.32 (0.54, 3.2) | 1.06 (0.55, 2.05) |
| Current HAART | 0.47 (0.21, 1.03) | 0.50 (0.23, 1.11) | 0.68 (0.23, 2.02) | 0.45 (0.2, 1.03) |
| Ever Combo | 1.18 (0.63, 2.23) | 1.21 (0.64, 2.27) | 0.88 (0.37, 2.12) | 1.02 (0.53, 1.96) |
| Ever Mono | 0.75 (0.38, 1.49) | 0.74 (0.37, 1.46) | 0.70 (0.28, 1.73) | 0.97 (0.48, 1.97) |
| Current CD4+ T cell count | 1.00 (0.9, 1.12) | 1.01 (0.9, 1.13) | 0.90 (0.77, 1.05) | 1.01 (0.9, 1.14) |
| Current CD8+ T cell count | 1.01 (0.94, 1.09) | 1.01 (0.94, 1.09) | 1.06 (0.96, 1.16) | 0.99 (0.92, 1.07) |
| Log10 HIV RNA | 0.74 (0.52, 1.05) | 0.75 (0.53, 1.06) | 0.86 (0.54, 1.36) | 0.66 (0.45, 0.96) |
Statistically significant at p<0.05.
Statistically significant at p<0.09.